JP2006519875A - 中枢神経系障害を治療するための選択的サイトカイン阻害剤 - Google Patents

中枢神経系障害を治療するための選択的サイトカイン阻害剤 Download PDF

Info

Publication number
JP2006519875A
JP2006519875A JP2006509174A JP2006509174A JP2006519875A JP 2006519875 A JP2006519875 A JP 2006519875A JP 2006509174 A JP2006509174 A JP 2006509174A JP 2006509174 A JP2006509174 A JP 2006509174A JP 2006519875 A JP2006519875 A JP 2006519875A
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
disease
group
selective cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509174A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519875A5 (enExample
Inventor
シェイファー，ピーター，エイチ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2006519875A publication Critical patent/JP2006519875A/ja
Publication of JP2006519875A5 publication Critical patent/JP2006519875A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006509174A 2003-03-06 2004-03-05 中枢神経系障害を治療するための選択的サイトカイン阻害剤 Pending JP2006519875A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45237403P 2003-03-06 2003-03-06
PCT/US2004/006782 WO2004080393A2 (en) 2003-03-06 2004-03-05 Selective cytokine inhibitory drugs for treating disorders of the central nervous system

Publications (2)

Publication Number Publication Date
JP2006519875A true JP2006519875A (ja) 2006-08-31
JP2006519875A5 JP2006519875A5 (enExample) 2006-10-12

Family

ID=32990646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509174A Pending JP2006519875A (ja) 2003-03-06 2004-03-05 中枢神経系障害を治療するための選択的サイトカイン阻害剤

Country Status (12)

Country Link
EP (1) EP1605935A4 (enExample)
JP (1) JP2006519875A (enExample)
KR (1) KR100831545B1 (enExample)
CN (1) CN1780616B (enExample)
AU (1) AU2004220607B2 (enExample)
BR (1) BRPI0408113A (enExample)
CA (1) CA2517845A1 (enExample)
IL (1) IL170710A0 (enExample)
MX (1) MXPA05009435A (enExample)
NZ (1) NZ542408A (enExample)
WO (1) WO2004080393A2 (enExample)
ZA (1) ZA200507322B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017141222A (ja) * 2016-02-09 2017-08-17 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤及びそのスクリーニング方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EA037187B1 (ru) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CA3079194A1 (en) * 2017-10-18 2019-04-25 Intrabio Limited Therapeutic agents for neurodegenerative diseases
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2022098106A1 (ko) * 2020-11-04 2022-05-12 주식회사 오에이티씨 클로르프로마진을 포함하는 신경 염증성 질환의 예방 또는 치료용 조성물
CN119280228B (zh) * 2024-11-06 2025-09-19 桂林医学院附属医院 帕金森病神经保护作用药物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500872A (ja) * 1993-07-02 1997-01-28 セルジーン コーポレイション ＴＮＦαの阻害剤としてのイミド類
WO1999006041A1 (en) * 1997-07-31 1999-02-11 Celgene Corporation SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS
WO2001034606A1 (en) * 1999-11-12 2001-05-17 Celgene Corporation Pharmaceutically active isoindoline derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
AR003951A1 (es) * 1995-05-26 1998-09-30 Pfizer Formulacion farmaceutica sinergica para el tratamiento de la enfermedad de parkinson y composiciones para prepararla.
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
JP3568749B2 (ja) * 1996-12-17 2004-09-22 株式会社デンソー 半導体のドライエッチング方法
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2003080048A1 (en) * 2002-03-20 2003-10-02 Celgene Corporation (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2003087333A2 (en) * 2002-04-12 2003-10-23 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500872A (ja) * 1993-07-02 1997-01-28 セルジーン コーポレイション ＴＮＦαの阻害剤としてのイミド類
WO1999006041A1 (en) * 1997-07-31 1999-02-11 Celgene Corporation SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS
WO2001034606A1 (en) * 1999-11-12 2001-05-17 Celgene Corporation Pharmaceutically active isoindoline derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN7009003976, Ｄｅｂｏｒａｈ Ｊ． Ｃｌａｒｋｅ， ｅｔ ａｌ．, "Ａ ｒｏｌｅ ｆｏｒ ｔｕｍｏｒ ｎｅｃｒｏｓｉｓ ｆａｃｔｏｒ ａｌｐｈａ ｉｎ ｄｅａｔｈ ｏｆ ｄｏｐａｍｉｎｅｒｇｉｃ ｎｅｕｒｏｎｓ ｆｏｌｌｏｗｉｎｇ ｎｅｕｒａｌ ｔｒａｎｓｐｌａｎｔａ", Ｅｘｐ Ｎｅｕｒｏｌ, 2002, Ｖｏｌ．１７６， Ｎｏ．１, ｐ．１５４−６２ *
JPN7009003977, ＫＲＩＳＨＮＡＮ ＳＲＩＲＡＭ， ｅｔ ａｌ．, "Ｍｉｃｅ ｄｅｆｉｃｉｅｎｔ ｉｎ ＴＮＦ ｒｅｃｅｐｔｏｒｓ ａｒｅ ｐｒｏｔｅｃｔｅｄ ａｇａｉｎｓｔ ｄｏｐａｍｉｎｅｒｇｉｃ ｎｅｕｒｏｔｏｘｉｃｉｔｙ： ｉｍｐｌｉｃａｔｉｏｎｓ ｆｏｒ Ｐ", Ｔｈｅ ＦＡＳＥＢ Ｊｏｕｒｎａｌ, 2002, １６, １４７４−１４７６ *
JPN7009003978, ＭＯＧＩ，Ｍ． ｅｔ ａｌ, "Ｔｕｍｏｒ ｎｅｃｒｏｓｉｓ ｆａｃｔｏｒ−ａｌｐｈａ （ＴＮＦ−ａｌｐｈａ） ｉｎｃｒｅａｓｅｓ ｂｏｔｈ ｉｎ ｔｈｅ ｂｒａｉｎ ａｎｄ ｉｎ ｔｈｅ ｃｅｒｅｂｒｏｓｐｉｎａｌ ｆｌｕｉｄ ｆ", Ｎｅｕｒｏｓｃｉ Ｌｅｔｔ, 1994, Ｖｏｌ．１６５， Ｎｏ．１−２, ｐ．２０８−１０ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017141222A (ja) * 2016-02-09 2017-08-17 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤及びそのスクリーニング方法

Also Published As

Publication number Publication date
AU2004220607B2 (en) 2009-06-11
CN1780616B (zh) 2010-05-12
CA2517845A1 (en) 2004-09-23
KR20050109971A (ko) 2005-11-22
EP1605935A4 (en) 2009-05-20
ZA200507322B (en) 2007-03-28
IL170710A0 (en) 2011-08-01
CN1780616A (zh) 2006-05-31
AU2004220607A1 (en) 2004-09-23
EP1605935A2 (en) 2005-12-21
NZ542408A (en) 2009-03-31
MXPA05009435A (es) 2005-11-23
WO2004080393A2 (en) 2004-09-23
WO2004080393A3 (en) 2004-12-02
KR100831545B1 (ko) 2008-05-21
BRPI0408113A (pt) 2006-03-01

Similar Documents

Publication Publication Date Title
US20080227816A1 (en) Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
RU2394570C2 (ru) Ингибиторы dpp-iv для лечения нейродегенерации и когнитивных расстройств
KR20070007880A (ko) 수면 기능장애 및 질환과 관련된 수면 기능장애의 치료,예방 또는 관리용 조성물 및 이의 치료, 예방 또는 관리방법
AU2004286819A1 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
AU2003284979B2 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CN1780616B (zh) 治疗中枢神经系统疾病的选择性细胞因子抑制药物
US20040175382A1 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
US20060106085A1 (en) Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
US20070190070A1 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN1921857A (zh) 使用沙利度胺治疗和控制中枢神经系统病症或疾病的方法和组合物
US20070161696A1 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
HK1102713A (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
MXPA06010091A (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
HK1100817A (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
MXPA06007166A (en) Immunomodulatory compounds for the treatment of central nervous system disorders
HK1123940A (en) Methods and compositions using pde4 modulators for treatment and management of central nervous system injury

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100519

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100712

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100730